This systematic review and exploratory meta-analysis, published in Frontiers in Psychiatry, evaluates whether transcranial direct current stimulation (tDCS) can effectively treat the cognitive deficits associated with schizophrenia. By analyzing 11 randomized controlled trials (RCTs), the researchers found that while tDCS significantly boosts specific cognitive tasks like working memory, its impact on general clinical symptoms remains highly dependent on the "dosage"—specifically the number and frequency of sessions.
TL;DR
This meta-analysis of 11 clinical trials suggests that adjunctive tDCS significantly improves cognitive function (specifically working memory) in patients with schizophrenia. While it doesn't consistently reduce general symptoms like hallucinations or depression, higher-intensity protocols (15 sessions or twice-daily stimulation) showed a significant reduction in overall disease severity.
What Problem Does This Paper Address?
Schizophrenia affects approximately 24 million people worldwide. While modern antipsychotics are relatively effective at managing "positive" symptoms (like hallucinations and delusions), they are notoriously poor at addressing cognitive impairment. Deficits in memory, attention, and executive function affect up to 85% of patients and are the primary barriers to long-term functional recovery and social reintegration.
Transcranial direct current stimulation (tDCS)—a non-invasive method that applies a low-intensity electrical current to the scalp—has emerged as a potential solution. However, previous studies have yielded "confused" and contradictory results. This paper seeks to resolve that ambiguity by aggregating the highest-quality evidence to determine if tDCS actually works and what specific protocols (session count and frequency) are most effective.
Methods
The authors conducted a systematic review following PRISMA guidelines, searching PubMed, Embase, and Web of Science for RCTs published through March 2025.
- Inclusion Criteria: Randomized trials comparing tDCS (alone or as an adjunct) against a sham/control group in patients diagnosed with schizophrenia.
- Analysis: They used RevMan 5.4 to perform the meta-analysis, calculating the Standardized Mean Deviation (SMD) to compare results across different studies.
- Quality Control: Study quality was assessed using the Cochrane Risk of Bias tool and the Jadad scale, while the overall strength of evidence was rated via GRADE.
- Subgroup Analysis: A key feature of this study was breaking down results by the number of sessions (10 vs. 15) and the frequency of intervention (once vs. twice daily).
Datasets
The study did not use a single dataset but synthesized data from 11 eligible RCTs involving a total of 468 individuals (240 in active tDCS groups, 228 in sham groups). The trials spanned from 2016 to 2024.
Evaluation metrics included:
- PASAT: Paced Auditory Serial Addition Task (Primary cognitive outcome).
- PANSS & SANS: Scales for positive and negative symptoms.
- CGI: Clinical Global Impression-Schizophrenia scale (Overall severity).
- AHRS & CDSS: Scales for hallucinations and depression.
Key Insights and Ideas
- Cognitive "Hardware" vs. Clinical "Software": The most striking finding was that tDCS had a massive effect on the PASAT score (SMD = 3.57), which measures working memory and processing speed. This suggests tDCS is effective at modulating the underlying neural circuitry of the brain's "executive control network."
- The "Dose" Matters: The researchers found a clear threshold for clinical efficacy. Protocols involving 15 sessions or twice-daily stimulation significantly reduced disease severity (CGI), whereas 10-session or once-daily protocols often failed to show a statistical difference from the sham.
- Targeting the DLPFC: Most successful trials targeted the Left Dorsolateral Prefrontal Cortex (DLPFC). The authors hypothesize that tDCS enhances neuroplasticity here by modulating NMDA receptor function, helping to "bridge the gap" where antipsychotics fail.
- Heterogeneity in Symptoms: tDCS did not show significant benefits for hallucinations (AHRS) or negative symptoms (SANS) across the board. This suggests that while tDCS is a powerful tool for cognitive enhancement, it may not be a "silver bullet" for all schizophrenia symptoms.
Key Results
- Cognition (PASAT): A significant improvement with an SMD of 3.57 (95% CI: 2.60, 4.54; $P < 0.00001$).
- Disease Severity (CGI):
- 15-session subgroup: Significant improvement (SMD = -0.56, $P = 0.0004$).
- Twice-daily subgroup: Significant improvement (SMD = -0.85, $P = 0.04$).
- Non-Significant Results: No statistically significant improvements were found for PANSS (general symptoms), SANS (negative symptoms), AHRS (hallucinations), or CDSS (depression) when looking at the aggregate data.
Limitations and Future Work
The authors are transparent about several hurdles:
- Small Sample Sizes: While the aggregate N is 468, some individual trials were very small (as few as 16 participants), which can inflate effect sizes.
- High Heterogeneity: There was significant variation in how tDCS was applied (current intensity, electrode placement, and duration), making it hard to define a single "gold standard" protocol.
- Publication Bias: The funnel plots suggested that studies with positive results might be overrepresented in the literature.
- Future Directions: The authors call for larger, multi-center RCTs with standardized protocols. They also suggest exploring home-based tDCS treatment, which could reduce the burden on patients who currently have to visit a clinic daily for weeks.
Summary updated